A Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Infantile-Onset Spinal Muscular Atrophy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Nusinersen (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
- Sponsors Biogen; Ionis Pharmaceuticals
- 28 Jul 2017 Planned End Date changed from 1 Jun 2017 to 31 Aug 2017.
- 28 Jul 2017 Planned primary completion date changed from 1 May 2017 to 31 Aug 2017.
- 03 Jan 2017 Planned End Date changed from 1 Nov 2016 to 1 Jun 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History